Bank of America CEO Brian Moynihan’s 2025 Compensation Rises 17% to $41 Million Amid Strong Profit Growth 
Valero Energy Expands Venezuelan Crude Imports as U.S. Sanctions Ease 
Macquarie-Led Consortium to Acquire Qube Holdings in A$11.7 Billion Deal 
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings 
Paramount Skydance Appoints Rene Augustine as SVP of Global Public Policy Amid Warner Bros Takeover Battle 
Sachem Head Boosts Warner Bros. Discovery Stake Amid Netflix Deal and Paramount Bid 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
Anduril Industries Seeks $8 Billion Funding at $60 Billion Valuation 
Treasury Wine Estates Profit Falls 46% as China and U.S. Inventory Reset Weighs on Earnings 
Grok AI Market Share Surges as xAI Faces Scrutiny Over Image Generation Controversy 
Lockheed Martin Secures $101M in U.S. Defense Contracts for AEGIS, F-35, and Missile Systems 
Senators Urge CFIUS Review of UAE Investment in Trump-Linked Crypto Firm World Liberty Financial 
Anthropic’s Claude AI Reportedly Used in U.S. Operation to Capture Nicolas Maduro 
GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks 
BlueScope Steel Forecasts Stronger Second-Half Earnings, Shares Rise Above Rejected Buyout Offer 
RANCHO CORDOVA, Calif., April 25, 2018 -- Cesca Therapeutics Inc. (“Cesca” or the “Company”) (NASDAQ:KOOL) today announced that the Company will be exhibiting its full suite of cellular processing solutions, including CAR-TXpress™ for the semi-automated manufacture of CAR-T cell therapies, X-BACS™ for cell isolation and other X-Series™ kits, at the following cell therapy conferences in May:
- International Society of Cellular Therapy 2018 Annual Meeting
May 2 – 5, 2018
Booth: 322
Palais des congrès de Montréal
1001, Place Jean-Paul-Riopelle
Montreal, Canada
For more information: www.isct2018.com
- American Society of Gene and Cell Therapy 2018 Annual Meeting
May 16 – 19, 2018
Booth: 417
Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
For more information: www.asgct.org/meetings-workshops/annual-meeting
- Phacilitate Automation Special Interest Group 2018
May 30 – 31, 2018
The Grove
Chandler’s Cross,
Watford WD3 4TG, Hertfordshire
London, UK
For more information: www.phacilitateautomation.com
About Cesca Therapeutics Inc.
Cesca Therapeutics develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. Its device division, ThermoGenesis, provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. The Company is developing an automated, functionally-closed CAR-TXpress™ platform that addresses the critical unmet need for better cellular manufacturing and controls for the emerging CAR-T immunotherapy market. Cesca is an affiliated company of China-based Boyalife Group.
Company Contact:
Cesca Therapeutics Inc.
Wendy Samford
916-858-5191
[email protected]
Investor Contact:
Rx Communications
Paula Schwartz
917-322-2216
[email protected]
